These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25408492)

  • 1. Likelihood approach for evaluating bioequivalence of highly variable drugs.
    Du L; Choi L
    Pharm Stat; 2015; 14(2):82-94. PubMed ID: 25408492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
    Lechat P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viewpoint: observations on scaled average bioequivalence.
    Patterson SD; Jones B
    Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
    Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
    AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case studies, practical issues and observations on population and individual bioequivalence.
    Zariffa NM; Patterson SD; Boyle D; Hyneck M
    Stat Med; 2000 Oct; 19(20):2811-20. PubMed ID: 11033577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribability and switchability of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
    Tothfalusi L; Endrenyi L
    AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling type I error in the reference-scaled bioequivalence evaluation of highly variable drugs.
    Ocaña J; Muñoz J
    Pharm Stat; 2019 Oct; 18(5):583-599. PubMed ID: 31190418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population and individual bioequivalence: lessons from real data and simulation studies.
    Zariffa NM; Patterson SD
    J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Regulatory Standpoint on Evaluating the Bioequivalence of Different Classes of Generic Drugs - Is the Evaluation in the Right Direction?
    Micheal F; Sayana M; Motial BM
    Curr Drug Metab; 2019; 20(10):835-844. PubMed ID: 31589117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Prescribability and Switchability by Using Multiple Bioequivalence Assessment Approaches.
    Micheal F; Sayana M; Prasad R; Motial BM
    Drug Metab Lett; 2021; 14(2):141-151. PubMed ID: 33745439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of Sarpogrelate in Healthy Chinese Subjects Under Fasting and Fed Conditions: A 4-Way Replicate Crossover Investigation by a Reference-Scaled Average Bioequivalence Approach.
    Ding YH; Liu B; Lou JF; Sun JX; Wu M; Zhu XX; Chen GL; Zhang H; Li XJ; Chen H; Liu CJ; Shen ZW; Li CY
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):713-720. PubMed ID: 30325583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the bioequivalence of highly-variable drugs and drug products.
    Tothfalusi L; Endrenyi L; Midha KK; Rawson MJ; Hubbard JW
    Pharm Res; 2001 Jun; 18(6):728-33. PubMed ID: 11474774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review.
    van der Meersch A; Dechartres A; Ravaud P
    PLoS One; 2011; 6(8):e23611. PubMed ID: 21858184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers.
    Huang YH; Li ZQ; Pan GX; Li YF; Liu Y; Sun JX; Gu XF; Li N; Wang BH
    Clin Ther; 2014 Sep; 36(9):1205-1216.e6. PubMed ID: 25234550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA mulls changes to bioequivalence standards.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.